Telavancin: in vitro activity against staphylococci in a biofilm model

Gander, Sarah; Kinnaird, Andrew; Finch, Roger

doi:10.1093/jac/dki198

Cited by 81 publications

(53 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This multifunctional mechanism of action may help to minimize the potential for the selection of resistance (16,27). In several studies, telavancin has exhibited in vitro activity superior to that of vancomycin (12,15,20,26,33).…”

mentioning

confidence: 99%

Efficacy of Telavancin in the Treatment of Experimental Endocarditis Due to Glycopeptide-Intermediate Staphylococcus aureus

Miró

García-de-la-Mària

Armero

et al. 2007

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The efficacy of telavancin, a novel lipoglycopeptide, was evaluated in experimental endocarditis in rabbits using two clinical isolates of glycopeptide-intermediate Staphylococcus aureus: ATCC 700788 and HIP 5836. Infected rabbits were treated for 2 days with telavancin (10 mg/kg of body weight once daily intravenously) or vancomycin (1 g twice daily intravenously), administered with a computer-controlled infusion pump system simulating human serum kinetics. Vegetations were harvested at 16 h postinoculation in the control group and at the end of treatment in the drug-treated group. For ATCC 700788, MICs and minimal bactericidal concentrations (MBCs), respectively, were 1 mg/liter and 4 mg/liter for telavancin and 8 mg/liter and 128 mg/liter for vancomycin. For HIP 5836, MICs and MBCs, respectively, were 4 mg/liter and 8 mg/liter for telavancin and 8 mg/liter and 128 mg/liter for vancomycin. Peak and trough levels were 90 g/ml and 6 g/ml, respectively, for telavancin and 46 g/ml and 6 g/ml, respectively, for vancomycin.

show abstract

mentioning

confidence: 99%

Efficacy of Telavancin in the Treatment of Experimental Endocarditis Due to Glycopeptide-Intermediate Staphylococcus aureus

Miró

García-de-la-Mària

Armero

et al. 2007

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Efficacy in such infections requires the antibiotic to be active against biofilm-embedded bacteria. In an in vitro biofilim Sorbarod infection model, telavancin was demonstrated to be more active than linezolid, vancomycin and teicoplanin against S. aureus (MSSA, MRSA, coagulase-negative staphylococci and GISA) [35].…”

Section: Rabbit Device Infection Modelmentioning

confidence: 99%

“…Concentration-dependent bactericidal effects were demonstrated in time-kill studies against target organisms, including methicillin-sensitive S. aureus (MSSA), MRSA, VISA and coagulase-negative staphylococci. Telavancin has been shown to retain bactericidal activity against slowly growing isolates of S. aureus in time-kill assays and in in vitro models of biofilm infection [34][35][36][37]. In a model of intracellular S. aureus infection, telavancin therapy resulted in >90% reduction in bacterial titers [38].…”

Section: Bactericidal Activitymentioning

confidence: 99%

Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection

Hegde

Janc

2014

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

“…Animal models evaluating TLV against biofilm-producing S. aureus (and the glycopeptideintermediate Staphylococcus aureus strain), S. epidermidis and Enterococcus faecalis revealed that TLV performed better than glycopeptides (VAN and teicoplanin) and linezolid, with MICs for TLV 8-16 times lower than VAN [Gander et al 2005;Chan et al 2015].…”

Section: Pharmacokinetics/pharmacodynamicsmentioning

confidence: 99%

Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience

Liapikou

Dimakou

Toumbis

2016

Ther Adv Respir Dis

View full text Add to dashboard Cite

Telavancin (TLV) is a lipoglycopeptide derivative of vancomycin (VAN), which has activity against Gram-positive aerobic bacteria, and is especially effective against methicillinresistant Staphylococcus aureus (MRSA) and Gram-positive bacteria resistant to VAN. Comparative clinical studies of TLV have demonstrated noninferiority compared with VAN in the treatment of hospital-acquired Gram-positive pneumonia, with high cure rates for TLV-treated patients with monomicrobial S. aureus infection, including isolates with reduced VAN susceptibility. The results based on the patients' clinical response were supported by supplemental post-hoc analyses of 28-day mortality. In Europe and the USA, TLV is approved as a useful alternative for patients with difficult-to-treat, hospital-acquired MRSA pneumonia when there are very few alternatives. The present article reviews TLV's pharmacological characteristics and clinical efficacy resulting from clinical trials giving a detailed picture of its properties and position in the management of hospital-acquired pneumonia.

show abstract

Telavancin: in vitro activity against staphylococci in a biofilm model

Abstract: Telavancin exhibited substantial antimicrobial activity against staphylococcal biofilms, including GISA strains. This study supports the case for the evaluation of telavancin in the treatment of staphylococcal biofilm-associated infections.

Cited by 81 publications

References 28 publications

Efficacy of Telavancin in the Treatment of Experimental Endocarditis Due to Glycopeptide-Intermediate Staphylococcus aureus

Efficacy of Telavancin in the Treatment of Experimental Endocarditis Due to Glycopeptide-Intermediate Staphylococcus aureus

Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection

Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience

Contact Info

Product

Resources

About